Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
July/August 2016, Volume 24, Issue 2
- CME Credit Available: 2.75 AMA PRA Category 1 Credits™
- Release Date: August 19, 2016
- Expiration Date: August 19, 2017
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
On completion of this activity, participants will be able to:
- List barriers to engagement and retention in care for hard-to-reach, HIV-infected populations and strategies to remove such barriers
- Identify lessons learned from the recent outbreak of HIV infection in Scott County, Indiana
- Describe the cost-effectiveness of, barriers to obtaining insurance coverage for, and ways in which practitioners can assist patients in obtaining treatment for hepatitis C virus (HCV) infection
- Describe the history and implications of the Patient Protection and Affordable Care Act in the United States
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV or HCV disease. This activity examines barriers to engagement and retention in care for hard-to-reach, HIV-infected populations; the outbreak of HIV infection in Scott Count, Indiana; the cost-effectiveness of and access to HCV therapy, and the implications of the Affordable Care Act.
This enduring material is designed for physicians and other health care practitioners who are actively involved in the medical care of people with HIV or HCV infection.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from August 19, 2016, to August 19, 2017. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, authors, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Dr del Rio has served as a consultant for InnaVirVax. (Updated 08/15/2016)
Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, and Monogram Biosciences, Inc. (Updated 06/15/16)
Dr Benson serves on a data and safety monitoring board for Glaxo-SmithKline/ViiV Healthcare. She has received research grants awarded to the University of California San Diego from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. (Updated 08/10/16) Her spouse, Robert T. Schooley, MD, was awarded research grants, paid to his institution, from Boehringer Ingelheim Pharmaceuticals, Inc, and Bristol-Myers Squibb. His institution has received payment for his consultative advice or data monitoring committee service from GlobeImmune, Gilead Sciences, Inc, and Monogram Biosciences. He serves as a consultant to CytoDyn, Hera Therapeutics, and Farmak. He has stock options from CytoDyn, Hera Therapeutics, and GlobeImmune. (Updated 09/01/15)
Dr Hirsch has no relevant financial affiliations to disclose. (Updated 06/15/16)
Dr Janowicz has no relevant financial affiliations to disclose. (Updated 07/07/16)
Dr Linas has no relevant financial affiliations to disclose. (Updated 07/11/16)
Dr Westmoreland has no relevant financial affiliations to disclose. (Updated 07/18/16)
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 08/19/16)
The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2016 Improving the Management of HIV Disease® CME program:
Gilead Sciences, Inc
Merck & Co, Inc
Independent educational grants for the 2016 Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes CME program:
Merck & Co, Inc
Gilead Sciences, Inc
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
If you have any questions about this activity, please contact the IAS–USA:
Mail: 425 California Street, Suite 1450, San Francisco, CA 94104-2120
By clicking “Begin,” I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.